Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers.
about
Levofloxacin can be used effectively as a positive control in thorough QT/QTc studies in healthy volunteersSterilizing activity of second-line regimens containing TMC207 in a murine model of tuberculosisResistance of M. leprae to quinolones: a question of relativity?Gender analysis of moxifloxacin clinical trialsMultiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.Levofloxacin and ciprofloxacin decrease procainamide and N-acetylprocainamide renal clearances.Efficient intermittent rifapentine-moxifloxacin-containing short-course regimen for treatment of tuberculosis in mice.Relationship of quantitative structure and pharmacokinetics in fluoroquinolone antibacterials.Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosisMoxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis.Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine modelRecombinant protective antigen anthrax vaccine improves survival when administered as a postexposure prophylaxis countermeasure with antibiotic in the New Zealand white rabbit model of inhalation anthrax.Investigational antimicrobial agents of 2013.Four-month moxifloxacin-based regimens for drug-sensitive tuberculosisMultiple-dose safety and pharmacokinetics of oral garenoxacin in healthy subjects.Incidence of moxifloxacin resistance in clinical Mycobacterium tuberculosis isolates in Houston, Texas.Which agents should we use for the treatment of multidrug-resistant Mycobacterium tuberculosis?Moxifloxacin in the treatment of skin and skin structure infections.Correlation between GyrA substitutions and ofloxacin, levofloxacin, and moxifloxacin cross-resistance in Mycobacterium tuberculosis.Comparison of the effects of levofloxacin on QT/QTc interval assessed in both healthy Japanese and Caucasian subjects (pagesNo proarrhythmic properties of the antibiotics Moxifloxacin or Azithromycin in anaesthetized dogs with chronic-AV block.Evaluation of Moxifloxacin-induced Biochemical Changes in MiceContribution of moxifloxacin or levofloxacin in second-line regimens with or without continuation of pyrazinamide in murine tuberculosis.Skin and skin structure infections: treatment with newer generation fluoroquinolones.New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.Molecular mechanisms of hepatocellular apoptosis induced by trovafloxacin-tumor necrosis factor-alpha interaction.Efficacy of levofloxacin in the treatment of BK viremia: a multicenter, double-blinded, randomized, placebo-controlled trialCiprofloxacin: review on developments in synthetic, analytical, and medicinal aspects.Interethnic differences in pharmacokinetics of antibacterials.Role of therapeutic drug monitoring in pulmonary infections: use and potential for expanded use of dried blood spot samples.Weighing the adverse cardiac effects of fluoroquinolones: A risk perspective.Urinary bactericidal activity of extended-release ciprofloxacin (1,000 milligrams) versus levofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose.The cardiovascular safety profile of renzapride, a novel treatment for irritable bowel syndrome.Identifying 24 h variation in the pharmacokinetics of levofloxacin: a population pharmacokinetic approach.Mutant prevention concentrations of levofloxacin, pazufloxacin and ciprofloxacin for A. baumannii and mutations in gyrA and parC genes.In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.Clinical Management of an Increasing Threat: Outpatient Urinary Tract Infections Due to Multidrug-Resistant Uropathogens.Covariate analysis of QTc and T-wave morphology: new possibilities in the evaluation of drugs that affect cardiac repolarization.Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis.
P2860
Q24607103-01848735-3806-4F1C-AC9C-B6A7EDA8DCECQ28477317-91DAB2BD-785A-4078-A776-31EE022C2BCFQ28535115-E4369EC2-2D5C-4CB8-A467-398EAFF20E45Q28538319-BC8BA16C-6FCE-43A6-9169-89432A38FA9FQ33559026-55E4B263-5A86-4C5A-9B29-39B4BC9D32CDQ33721968-B00AA2B7-FC98-4657-8C9B-AEEF4A1323D4Q34077125-FF12E8E4-277B-47BD-B492-74FC61488B65Q34098582-539E30B5-6743-4CD4-BA55-83331E82B9C8Q34108091-BA223965-AB2E-4404-9F57-68276BD92508Q34272283-B31A9541-FE13-4163-977B-0CFB338A0AFBQ34290003-C10E78B9-9F35-4879-8C00-40391300CF78Q34303179-1606781F-FD2B-4487-AF27-9776178BC90EQ34375204-3AD3CA4A-EA17-4D62-8A77-DFB2F7B7BFF6Q34777926-9C4D5894-CFB5-4A28-A5DA-BF40BC15F6E7Q35102747-7E66D8E3-44F1-468B-8AF0-8D15B7C7BBA6Q35139691-EAB91089-60CB-42DF-84AC-A35E26C168E0Q35849799-C81178F8-F4D2-4203-BA4A-1F858BF1E24AQ35919259-5D5942B5-7001-4E5C-9E1B-B5F90A8F9A6AQ35960685-0627D90C-E60A-4DB1-B644-3F8AB4347D1CQ36017405-3551E0C1-9FD6-4969-BA03-80A382503B78Q36054313-E6711C9F-6D88-4AA5-9229-841C58D7444BQ36865298-731A03B0-71B1-48E8-BC6B-B4D9662329BDQ37074826-2DDEF31A-96B8-4545-8E41-940B16D1400DQ37116838-089E36BE-703C-4A1B-9881-95B062A925B0Q37346929-AB26CDFE-97EF-4862-8DF6-6D4E7AD7359BQ37392763-9BD35441-6D7C-4B5A-B4E2-71B2FE0ED9E8Q37411993-94A459E8-4193-43A6-B892-C4D1E004F18EQ37621540-609E9F6A-6604-4CA6-904E-6C7D80C83E79Q37710505-B885039B-94D7-4540-B1F5-4699A7FB829AQ38266806-2C857954-381C-4C81-8E0D-9DD117E9D9D2Q38369608-E4D8C8BF-12DA-41DD-8AEE-186C11CA250EQ38502981-D8663194-7D15-4C8E-95B6-9776BB267805Q39078187-1E87FCFF-7A0A-429B-A771-24C2BC1C000DQ40045695-8B8C4DF2-3C3B-40C2-938A-5FA2D8170324Q40225657-7A9EE07E-FD1C-493B-BD33-591F5CBD5F9FQ41686050-EF79AAE1-DF2D-40B6-A0AD-A2BEADCBA8E4Q41899401-F04DA770-3DAB-4741-87A7-E20202487DBAQ42102558-8AD3EEC2-BDE1-408C-AD2A-CB6A244ABE4FQ43059195-E0F59B5F-4D0B-4CC4-83B1-BEDCA57FF0E7Q46029821-C59D4CF7-AAD6-415A-A041-C3B806D0221A
P2860
Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers.
description
2000 nî lūn-bûn
@nan
2000 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Comparative pharmacokinetics o ...... tration in healthy volunteers.
@ast
Comparative pharmacokinetics o ...... tration in healthy volunteers.
@en
type
label
Comparative pharmacokinetics o ...... tration in healthy volunteers.
@ast
Comparative pharmacokinetics o ...... tration in healthy volunteers.
@en
prefLabel
Comparative pharmacokinetics o ...... tration in healthy volunteers.
@ast
Comparative pharmacokinetics o ...... tration in healthy volunteers.
@en
P2093
P2860
P1476
Comparative pharmacokinetics o ...... tration in healthy volunteers.
@en
P2093
P2860
P304
P356
10.1128/AAC.44.10.2600-2603.2000
P407
P577
2000-10-01T00:00:00Z